Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2022 17:30 ET | Source: Allarity Therapeutics, Inc.

Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full...
May 16, 2022 19:40 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Cambridge, MA U.S.A. (May 16, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
April 22, 2022 17:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
March 15, 2022 08:32 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Update on Dovitinib Program

FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...
February 18, 2022 16:15 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

Refusal to File letters concern the new drug application for dovitinib and the DRP®-Dovitinib companion diagnostic pre-market approval applicationAllarity intends to seek guidance from the FDA on...
January 03, 2022 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity...
December 22, 2021 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA)...
December 21, 2021 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market

Press release Cambridge, MA U.S.A. (December 21, 2021) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company developing novel oncology...
December 13, 2021 17:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North

Press release Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”)...
December 11, 2021 09:35 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North

Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders...